Answers are grounded in this paper and cite their sources.
Background & Aims Rituximab-containing chemotherapy predisposes chronic hepatitis B (CHB) patients to severe hepatitis B virus (HBV) reactivation, but the clinical outcomes after prophylactic nucleos(t)ide analogue (Nuc) withdrawal remain unclear. We aimed to evaluate the impact of rituximab on off-Nuc clinical course by comparing lymphoma-CHB patients treated with rituximab, without rituximab, and non-lymphoma HBeAg-negative CHB patients. Methods We compared off-Nuc outcomes among rituximab-treated lymphoma–CHB (n=132), non-rituximab lymphoma (n=26), and HBeAg-negative CHB controls (n=939) using propensity score matching (PSM) and inverse probability treatment weighting (IPTW). Sensitivity analyses using the Fine and Gray competing risk model confirmed the robustness of predictors. Results The 2-year severe flare incidence was significantly higher in rituximab-treated patients than in non-rituximab lymphoma (after IPTW, 22% vs. 8%, p<0.01) or HBeAg-negative CHB (after PSM, 32% vs. 7%, p<0.01). Notably, 88% of relapse events occurred within the first year after discontinuation. Rituximab-treated patients showed steeper HBV DNA rebound kinetics (57% vs. 25% with ΔHBV DNA ≥1 log 10 IU/month, p=0.23 vs. non-rituximab; 61% vs. 17%, p<0.01 vs. HBeAg-negative CHB). Use of lower genetic barrier Nucs, baseline HBV DNA ≥4 log 10 IU/mL, and end-of-treatment HBsAg ≥100 IU/mL predicted clinical relapse, while non-entecavir use and △HBV DNA ≥1 log 10 IU/month at relapse identified those at highest risk of severe flare. Conclusions Rituximab-exposed lymphoma–CHB patients showed steeper off-therapy HBV DNA rebound and a higher risk of severe hepatitis flares after prophylactic Nuc withdrawal than those without rituximab and HBeAg-negative CHB patients. Close monitoring during the first year after Nuc cessation should be considered for rituximab-treated lymphoma–CHB, when most relapses occur. Impact and Implications Rituximab-treated patients had higher risk of severe flare with a steeper off-therapy HBV rebound kinetics than in non-rituximab lymphoma or HBeAg-negative CHB. Most clinical relapses occurred within the first year after discontinuation of prophylactic Nuc. Use of lower genetic barrier Nucs (LAM or LdT), a pretherapy HBV DNA ≥ 4 log 10 IU/mL, and an EOT HBsAg ≥ 100 IU/mL were significant predictors of CR in CHB patients with lymphoma. Close monitoring during the first year after Nuc cessation should be considered, particularly for rituximab-treated lymphoma–CHB.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: